MX2009009466A - Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. - Google Patents

Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.

Info

Publication number
MX2009009466A
MX2009009466A MX2009009466A MX2009009466A MX2009009466A MX 2009009466 A MX2009009466 A MX 2009009466A MX 2009009466 A MX2009009466 A MX 2009009466A MX 2009009466 A MX2009009466 A MX 2009009466A MX 2009009466 A MX2009009466 A MX 2009009466A
Authority
MX
Mexico
Prior art keywords
compounds useful
iron disorders
tricyclic compounds
treating iron
compounds
Prior art date
Application number
MX2009009466A
Other languages
English (en)
Inventor
Vishnumurthy Kodumuru
Rajender Kamboj
Zaihui Zhang
Serguei Sviridov
Shifeng Liu
Nagasree Chakka
Mikhail Chafeev
Jianmin Fu
Jianyu Sun
Jean-Jacques Cadieux
Johnathan Langille
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MX2009009466A publication Critical patent/MX2009009466A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C07D327/08—[b,e]-condensed with two six-membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/08—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing three- or four-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Abstract

Compuestos de fórmula (I): (ver fórmula (I)) donde n, m R1, R2, R3, R4, R5, R6, R7 y R8 como se definen aquí, como un estereoisómero, enantiomero, tautómero del mismo o mezclas de los mismos; o una sal, solvato o profármaco aceptable para uso farmacéutico del mismo, para el tratamiento de trastornos del hierro; esta invención también está dirigida a composiciones farmacéuticas que comprenden los compuestos y método de utilización de los compuestos para tratar trastornos del hierro.
MX2009009466A 2007-03-07 2008-03-07 Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. MX2009009466A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89358507P 2007-03-07 2007-03-07
PCT/US2008/056250 WO2008109840A1 (en) 2007-03-07 2008-03-07 Tricyclic compounds useful in treating iron disorders

Publications (1)

Publication Number Publication Date
MX2009009466A true MX2009009466A (es) 2009-09-15

Family

ID=39512833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009466A MX2009009466A (es) 2007-03-07 2008-03-07 Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.

Country Status (13)

Country Link
US (1) US20090069408A1 (es)
EP (1) EP2061755A1 (es)
JP (1) JP2010520884A (es)
CN (1) CN101616892A (es)
AR (1) AR065628A1 (es)
AU (1) AU2008222666A1 (es)
BR (1) BRPI0808043A2 (es)
CA (1) CA2678895A1 (es)
CL (1) CL2008000666A1 (es)
MX (1) MX2009009466A (es)
RU (1) RU2009136996A (es)
TW (1) TW200845961A (es)
WO (1) WO2008109840A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2068855A2 (en) * 2007-06-05 2009-06-17 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
AR077892A1 (es) 2009-08-20 2011-09-28 Vifor Int Ag Quinolinas antagonistas de la hepcidina
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
US20120214798A1 (en) 2009-09-07 2012-08-23 Vifor (International) Ag Novel Ethanediamone Hepcidine Antagonists
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
CN114668761A (zh) 2015-10-23 2022-06-28 威佛（国际）股份公司 新的膜铁转运蛋白抑制剂
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
CN114163417B (zh) * 2021-12-06 2023-08-04 郑州海阔光电材料有限公司 一种3-溴硫芴的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
EP0661284A1 (en) * 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
US6310243B1 (en) * 1994-09-23 2001-10-30 Nycomed Imaging As Iodinated x-ray contrast media
US6080587A (en) * 1998-01-23 2000-06-27 Eli Lilly And Company Method for preparing and selecting pharmaceutically useful sulfur-bridged bi- and triaromatic ring compounds from a structurally diverse universal library
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US20060269498A1 (en) * 2005-05-17 2006-11-30 Gerard Malle Hair shaping composition comprising at least one polyguanidine other than hydroxide
EP2068855A2 (en) * 2007-06-05 2009-06-17 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders

Also Published As

Publication number Publication date
CA2678895A1 (en) 2008-09-12
EP2061755A1 (en) 2009-05-27
CN101616892A (zh) 2009-12-30
RU2009136996A (ru) 2011-04-20
BRPI0808043A2 (pt) 2014-06-24
US20090069408A1 (en) 2009-03-12
JP2010520884A (ja) 2010-06-17
WO2008109840A1 (en) 2008-09-12
AR065628A1 (es) 2009-06-17
CL2008000666A1 (es) 2008-06-13
AU2008222666A1 (en) 2008-09-12
TW200845961A (en) 2008-12-01

Similar Documents

Publication Publication Date Title
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
MX2009010083A (es) Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro.
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
WO2008121861A3 (en) Pyrazole and pyrrole compounds useful in treating iron disorders
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
WO2008147864A3 (en) Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
JO3032B1 (ar) مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
TW200531689A (en) Therapeutic agents
TW200612936A (en) Indole derivatives
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
UA98373C2 (ru) Конденсированные гетероциклические производные и их применение как c-met ингибиторов
MY177111A (en) Substituted amide derivatives and methods of use
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MX2009004822A (es) Compuestos de fenilpropionamida y usos de los mismos.
UA115881C2 (uk) Алкоксипіразоли як активатори розчинної гуанілатциклази
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
TW200637817A (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal